| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Vanda Pharmaceuticals Inc (NASDAQ: VNDA)
VNDA Technical Analysis
5
| As on 9th Jun 2023 VNDA SHARE Price closed @ 6.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 11.41 & Strong Sell for SHORT-TERM with Stoploss of 14.22 we also expect STOCK to react on Following IMPORTANT LEVELS. |
VNDASHARE Price
| Open | 6.55 | Change | Price | % |
| High | 6.56 | 1 Day | 0.00 | 0.00 |
| Low | 6.47 | 1 Week | 0.55 | 9.24 |
| Close | 6.50 | 1 Month | 0.30 | 4.84 |
| Volume | 275900 | 1 Year | -10.49 | -61.74 |
| 52 Week High 17.98 | 52 Week Low 5.90 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| VNDA Daily Charts |
VNDA Intraday Charts |
Whats New @ Bazaartrend |
VNDA Free Analysis |
|
|
VNDA Important Levels Intraday
| RESISTANCE | 6.67 |
| RESISTANCE | 6.62 |
| RESISTANCE | 6.58 |
| RESISTANCE | 6.55 |
| SUPPORT | 6.45 |
| SUPPORT | 6.42 |
| SUPPORT | 6.38 |
| SUPPORT | 6.33 |
VNDA Forecast April 2024
| 4th UP Forecast | 15.65 |
| 3rd UP Forecast | 12.72 |
| 2nd UP Forecast | 10.9 |
| 1st UP Forecast | 9.09 |
| 1st DOWN Forecast | 3.91 |
| 2nd DOWN Forecast | 2.1 |
| 3rd DOWN Forecast | 0.28 |
| 4th DOWN Forecast | -2.65 |
VNDA Weekly Forecast
| 4th UP Forecast | 10.95 |
| 3rd UP Forecast | 9.52 |
| 2nd UP Forecast | 8.64 |
| 1st UP Forecast | 7.76 |
| 1st DOWN Forecast | 5.24 |
| 2nd DOWN Forecast | 4.36 |
| 3rd DOWN Forecast | 3.48 |
| 4th DOWN Forecast | 2.05 |
VNDA Forecast2024
| 4th UP Forecast | 30.11 |
| 3rd UP Forecast | 22.54 |
| 2nd UP Forecast | 17.86 |
| 1st UP Forecast | 13.18 |
| 1st DOWN Forecast | -0.18 |
| 2nd DOWN Forecast | -4.86 |
| 3rd DOWN Forecast | -9.54 |
| 4th DOWN Forecast | -17.11 |
Vanda Pharmaceuticals Inc ( NASDAQ USA Symbol : VNDA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
VNDA Business Profile
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. Address: 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service